Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO

Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26. The company is also progressing with Pen-G commercialization and aims for an EBITDA margin of 21-22%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x5Pmwfy
via IFTTT